ArticleBiomedical engineering letters2024
Characterization of the phagocytic ability of white blood cells separated using a single curvature spiral microfluidic device.
Article in Biomedical engineering letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Cascaded Dual Spiral Microfluidic Chip for Continuous Separation of Multicomponent Microparticles.Micromachines · 2026Article
- Robust and efficient separation of white blood cells from blood using a microfluidic chip with a pair of linearly tapered crossflow filter arrays.Mikrochimica acta · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present work describes a microfluidic device developed for separating white blood cells (WBCs) for the Nitroblue Tetrazolium (NBT) bioassay, which quantifies the phagocytic ability of cells. The NBT test requires a small number of phagocytic cells but is highly susceptible to the presence of red blood cells (RBCs). Our inertial microfluidic device can deliver a WBC sample by removing 99.99% of RBCs and subsequently reducing the ratio of RBC to WBC from 848:1 to 2:3. The microdevice operates on a relatively higher hematocrit concentration (1% Hct) of blood. Compared to conventional WBC separation methods, the microdevice's passive, label-free nature preserves the cell properties of the original sample. A single-turn spiral microfluidic device with a rectangular cross-section is simple to fabricate, cost-effective, and easy to operate. The reported microfluidic device requires only a single drop of whole blood (⁓20 µl) obtained via the finger prick method for efficient phagocytic analysis. Also, the microdevice reported in this study achieves WBC separation in under 10 min, omitting the need for RBC lysis, density gradient centrifugation, or expensive antibodies. Supplementary Information: The online version contains supplementary material available at 10.1007/s13534-024-00414-y.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.